# Lantern Pharma Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Lantern Pharma Inc.). ## Overview Lantern Pharma Inc. is a clinical-stage biopharmaceutical company focused on using its RADR® AI/ML platform to discover and develop oncology drug candidates. It combines de novo biomarker-guided programs with a “rescue” strategy for previously studied compounds that may be repurposed for more targeted cancer trials. ## Products & services • LP-300 oncology drug candidate • LP-184 oncology drug candidate • LP-284 oncology drug candidate • LP-100 oncology program • ADC program • RADR® AI-driven drug discovery platform - **Clinical-stage oncology programs** (70%) — Drug candidates in preclinical and clinical development for cancer indications. - **AI-enabled discovery platform** (20%) — RADR® and related machine-learning tools used to identify and de-risk candidates. - **Rescue and repurposing pipeline** (10%) — Previously studied compounds being re-evaluated with biomarker and AI methods. - LP-300 oncology drug candidate - LP-184 oncology drug candidate - LP-284 oncology drug candidate - LP-100 oncology program - ADC program - RADR® AI-driven drug discovery platform ## Customers Lantern Pharma does not sell commercial medicines today; its primary “customers” are investors, research partners, and future licensing or commercialization partners that support development of its pipeline. In the longer term, the end customers would be oncology patients and the physicians and hospitals treating them, if any candidate reaches approval. The company also seeks grant funding and may pursue collaborations to help finance development. - **Capital providers** (primary) — Equity investors and other financiers fund the company because it has no product revenue and needs capital for development. - **Strategic partners** (secondary) — Pharma or biotech partners may license, co-develop, or acquire programs to share development risk and access the RADR® platform. - **Grant agencies** (secondary) — Public or private grant funders may support specific research or translational work to extend runway. - **Future oncology treatment market** (emerging) — If approved, hospitals, physicians, and patients would use the therapies for biomarker-guided cancer treatment. - Investors funding R&D and working capital - Potential pharma partners for licensing or collaboration - Grant-making bodies supporting research programs - Future oncologists, hospitals, and patients if products are approved - Clinical trial sites and research service providers ## Geography Lantern Pharma is headquartered in the United States and reports no product revenue to date. Its development work is global in scope, with the company specifically noting clinical testing activity in Taiwan for LP-300, which creates geographic execution and geopolitical exposure. The business is still largely U.S.-financed, but trial operations and future commercialization could extend into additional markets. - United States is the corporate and financing base - Clinical testing activity includes Taiwan for LP-300 - No disclosed product revenue by country to date - Future commercialization could expand beyond the U.S. - Geographic execution matters because trials and regulation vary by market ## Strategy The company’s strategy is to build an oncology pipeline using RADR® and other machine-learning methods, while also identifying historical drug candidates that can be revived with better biomarker selection and more targeted trials. Management is focused on advancing LP-300, LP-184, and LP-284, expanding the platform, and preserving enough capital to keep development moving toward regulatory approval. The strategy is designed to reduce clinical risk and improve the odds of finding the right patient for the right therapy. - **Advance lead oncology candidates** (short-term) — Clinical progress is the main value driver because the company currently has no product revenue. - **Use AI to de-risk development** (medium-term) — RADR® and biomarker-guided selection are intended to improve trial success rates and reduce wasted spend. - **Secure additional capital** (short-term) — The company expects substantial future funding needs to support trials and operations. - Advance LP-300, LP-184, and LP-284 through development - Use RADR® to improve target selection and trial design - Rescue prior compounds with existing safety and ADME data - Expand the pipeline through in-licensing or acquisition - Seek grants, equity, and possible credit facilities for funding - Build IP and future commercialization capabilities ## Risks Lantern Pharma is a pre-revenue biotech, so its business depends on successful clinical development, regulatory approval, and access to external capital. The company also faces execution risk from trial enrollment, manufacturing, competition, and the possibility that its AI-driven approach does not translate into approved therapies. Geographic exposure, including Taiwan-based clinical work, adds geopolitical and operational uncertainty. - **Clinical development failure** [critical] — LP-300, LP-184, LP-284 and other programs may not show sufficient efficacy or safety to advance. - **Capital dilution and liquidity pressure** [high] — The company expects substantial additional funding needs and may need to raise equity on unfavorable terms. - **Geopolitical and trial execution risk in Taiwan** [medium] — Management explicitly cited Taiwan as a location for clinical testing, which can affect timelines and operations. - **Commercialization uncertainty** [high] — Even if candidates succeed clinically, the company must still build manufacturing, sales, and distribution capabilities. - No product revenue; value depends on future approvals - Clinical trials may fail, delay, or produce inconclusive results - Additional funding is needed and may be dilutive - Taiwan trial activity adds geopolitical and execution risk - Competition and manufacturing constraints can limit success - AI/biomarker strategy may not improve outcomes as expected ## Accounting As a pre-revenue biotech, Lantern Pharma’s reported results are dominated by research and development expense, stock-based financing, and recurring operating losses. Quarterly comparability is affected by the timing of clinical work and service-provider spending across programs such as LP-300, LP-184, and LP-284. Investors should also watch capital raise accounting, grant revenue if any, and any future impairment or valuation judgments tied to intangible assets or development programs. - **Revenue recognition** — Reported revenue may remain minimal until a partnership or approval occurs. - **Research and development expense timing** — Quarterly results may not be directly comparable across periods. - **Equity financing and dilution** — Share count and per-share metrics can change materially. - **Going-concern style liquidity assessment** — Runway and financing assumptions are central to valuation. - No revenue recognized in the reported quarter - R&D spend fluctuates with trial timing and program mix - Stock issuance and equity financing affect dilution - Grant or license revenue may be episodic and non-recurring - Future impairment judgments could affect development assets --- *Last updated: 2026-04-28T20:22:17.266623+00:00*